CL2017000192A1 - Compuestos de 6,7-dihidropirazolo[1,5-a]pirazin-4(5h)-ona y su uso como moduladores alostéricos negativos de receptores mglu2r2 - Google Patents
Compuestos de 6,7-dihidropirazolo[1,5-a]pirazin-4(5h)-ona y su uso como moduladores alostéricos negativos de receptores mglu2r2Info
- Publication number
- CL2017000192A1 CL2017000192A1 CL2017000192A CL2017000192A CL2017000192A1 CL 2017000192 A1 CL2017000192 A1 CL 2017000192A1 CL 2017000192 A CL2017000192 A CL 2017000192A CL 2017000192 A CL2017000192 A CL 2017000192A CL 2017000192 A1 CL2017000192 A1 CL 2017000192A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- mglu2r2
- dihydropyrazolo
- pyrazin
- receptors
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- GLQXAHBYDJPCHG-UHFFFAOYSA-N 6,7-dihydro-5h-pyrazolo[1,5-a]pyrazin-4-one Chemical compound O=C1NCCN2N=CC=C12 GLQXAHBYDJPCHG-UHFFFAOYSA-N 0.000 title 1
- 229940126662 negative allosteric modulator Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14179598 | 2014-08-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017000192A1 true CL2017000192A1 (es) | 2017-07-28 |
Family
ID=51257437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017000192A CL2017000192A1 (es) | 2014-08-01 | 2017-01-25 | Compuestos de 6,7-dihidropirazolo[1,5-a]pirazin-4(5h)-ona y su uso como moduladores alostéricos negativos de receptores mglu2r2 |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US10005786B2 (OSRAM) |
| EP (1) | EP3177623B1 (OSRAM) |
| JP (1) | JP6662846B2 (OSRAM) |
| KR (1) | KR102531689B1 (OSRAM) |
| CN (1) | CN106573936B (OSRAM) |
| AR (1) | AR101392A1 (OSRAM) |
| AU (1) | AU2015295298B2 (OSRAM) |
| BR (1) | BR112017001726A2 (OSRAM) |
| CA (1) | CA2954093C (OSRAM) |
| CL (1) | CL2017000192A1 (OSRAM) |
| CY (1) | CY1121649T1 (OSRAM) |
| DK (1) | DK3177623T3 (OSRAM) |
| EA (1) | EA031087B1 (OSRAM) |
| ES (1) | ES2708215T3 (OSRAM) |
| HR (1) | HRP20181997T1 (OSRAM) |
| HU (1) | HUE042871T2 (OSRAM) |
| IL (1) | IL250298A0 (OSRAM) |
| JO (1) | JOP20150179B1 (OSRAM) |
| LT (1) | LT3177623T (OSRAM) |
| MA (1) | MA39582B1 (OSRAM) |
| ME (1) | ME03320B (OSRAM) |
| MX (1) | MX376289B (OSRAM) |
| NZ (1) | NZ728122A (OSRAM) |
| PH (1) | PH12017500161B1 (OSRAM) |
| PL (1) | PL3177623T3 (OSRAM) |
| PT (1) | PT3177623T (OSRAM) |
| RS (1) | RS58279B1 (OSRAM) |
| SG (1) | SG11201700638YA (OSRAM) |
| SI (1) | SI3177623T1 (OSRAM) |
| SM (1) | SMT201900038T1 (OSRAM) |
| TR (1) | TR201901074T4 (OSRAM) |
| TW (1) | TWI696624B (OSRAM) |
| WO (1) | WO2016016380A1 (OSRAM) |
| ZA (1) | ZA201700759B (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015208233B2 (en) | 2014-01-21 | 2019-08-29 | Janssen Pharmaceutica Nv | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
| ME03518B (me) | 2014-01-21 | 2020-04-20 | Janssen Pharmaceutica Nv | Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena |
| JOP20150177B1 (ar) | 2014-08-01 | 2021-08-17 | Janssen Pharmaceutica Nv | مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2 |
| JOP20150179B1 (ar) | 2014-08-01 | 2021-08-17 | Janssen Pharmaceutica Nv | مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2 |
| AU2015357167B2 (en) | 2014-12-03 | 2020-06-25 | Janssen Pharmaceutica Nv | 6,7-dihydropyrazolo(1,5-alpha)pyrazin-4(5H)-one compounds and their use as negative allosteric modulators of mGluR2 receptors |
| ES2727158T3 (es) | 2014-12-03 | 2019-10-14 | Janssen Pharmaceutica Nv | Ligandos para PET de mGluR2 radiomarcados |
| US11045562B2 (en) | 2015-12-18 | 2021-06-29 | Janssen Pharmaceutica Nv | Radiolabelled mGluR2/3 PET ligands |
| WO2017103182A1 (en) | 2015-12-18 | 2017-06-22 | Janssen Pharmaceutica Nv | Radiolabelled mglur2/3 pet ligands |
| JP2020011902A (ja) * | 2016-10-26 | 2020-01-23 | 大日本住友製薬株式会社 | 縮環ピロール誘導体およびその医薬用途 |
| CN107298682B (zh) * | 2017-06-29 | 2019-03-01 | 天津药明康德新药开发有限公司 | 一种4,5,6,7-四氢吡唑并[1,5-a]吡嗪-2-甲酸乙酯的合成方法 |
| JP7242548B2 (ja) | 2017-11-24 | 2023-03-20 | 住友ファーマ株式会社 | ６，７－ジヒドロピラゾロ［１，５－ａ］ピラジノン誘導体及びその医薬用途 |
| IL276223B2 (en) * | 2018-01-26 | 2024-03-01 | Recordati Ind Chimica E Farmaceutica S P A | TRIAZOLE, IMIDAZOLE AND PYRROLE CONDENSED PIPERAZINE DERIVATIVES AND THEIR USE AS MODULATORS OF mGlu5 RECEPTORS |
| GB201905721D0 (en) | 2019-04-24 | 2019-06-05 | Univ Dundee | Compounds |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0756200B1 (en) | 1995-07-26 | 1999-11-10 | Konica Corporation | Silver halide color photographic light-sensitive material |
| US6482821B2 (en) | 1996-12-20 | 2002-11-19 | Hoechst Aktiengellschaft | Vitronectin receptor antagonists, their preparation and their use |
| DE19653647A1 (de) | 1996-12-20 | 1998-06-25 | Hoechst Ag | Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung |
| US6754375B1 (en) | 1999-07-16 | 2004-06-22 | Packard Bioscience Company | Method and system for interactively developing at least one grid pattern and computer-readable storage medium having a program for executing the method |
| US6831074B2 (en) | 2001-03-16 | 2004-12-14 | Pfizer Inc | Pharmaceutically active compounds |
| US20030114448A1 (en) | 2001-05-31 | 2003-06-19 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| TWI372050B (en) | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
| WO2005061507A1 (en) | 2003-12-16 | 2005-07-07 | Pfizer Products Inc. | Bicyclic pyrazol-4-one cannabinoid receptor ligands and uses thereof |
| SI1761541T1 (sl) | 2004-06-21 | 2008-06-30 | Hoffmann La Roche | Derivati pirazolo-pirimidina |
| WO2006030847A1 (ja) | 2004-09-17 | 2006-03-23 | Dainippon Sumitomo Pharma Co., Ltd. | 新規二環性ピラゾール誘導体 |
| DE102004054665A1 (de) | 2004-11-12 | 2006-05-18 | Bayer Cropscience Gmbh | Substituierte bi- und tricyclische Pyrazol-Derivate Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren |
| ES2365406T3 (es) * | 2005-02-11 | 2011-10-04 | F. Hoffmann-La Roche Ag | Derivados de pirazolo-pirimidina como antagonistas de mglur2. |
| KR100973609B1 (ko) | 2005-03-23 | 2010-08-03 | 에프. 호프만-라 로슈 아게 | ｍＧｌｕＲ2 길항제로서 아세틸렌일-피라졸로-피리미딘유도체 |
| WO2007084314A2 (en) | 2006-01-12 | 2007-07-26 | Incyte Corporation | MODULATORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME |
| JP5523829B2 (ja) | 2006-06-29 | 2014-06-18 | アステックス、セラピューティックス、リミテッド | 複合薬剤 |
| EP2155747B1 (en) | 2007-05-10 | 2012-10-24 | GE Healthcare Limited | Imidazol (1,2-a)pyridines and related compounds with activity at cannabinoid cb2 receptors |
| EP2085390A1 (en) | 2008-01-31 | 2009-08-05 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Labelled analogues of halobenzamides as multimodal radiopharmaceuticals and their precursors |
| US9446995B2 (en) | 2012-05-21 | 2016-09-20 | Illinois Institute Of Technology | Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions |
| WO2009118292A1 (en) | 2008-03-24 | 2009-10-01 | Novartis Ag | Arylsulfonamide-based matrix metalloprotease inhibitors |
| JPWO2010024258A1 (ja) | 2008-08-29 | 2012-01-26 | 塩野義製薬株式会社 | Ｐｉ３ｋ阻害活性を有する縮環アゾール誘導体 |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| EP2430022B1 (en) | 2009-05-12 | 2013-11-20 | Janssen Pharmaceuticals, Inc. | 1,2,4-Triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders |
| JP2013537210A (ja) | 2010-09-16 | 2013-09-30 | ノバルティス アーゲー | １７α−ヒドロキシラーゼ／Ｃ１７，２０−リアーゼ阻害剤 |
| US20130230459A1 (en) | 2010-11-08 | 2013-09-05 | Janssen Pharmaceuticals, Inc. | RADIOLABELLED mGluR2 PET LIGANDS |
| AU2011343477A1 (en) | 2010-12-17 | 2013-07-04 | Vanderbilt University | Bicyclic triazole and pyrazole lactams as allosteric modulators of mGluR5 receptors |
| GB201106817D0 (en) | 2011-04-21 | 2011-06-01 | Astex Therapeutics Ltd | New compound |
| WO2012172093A1 (en) | 2011-06-17 | 2012-12-20 | Merz Pharma Gmbh & Co. Kgaa | Dihydroindolizine derivate as metabotropic glutamate receptor modulators |
| WO2013012918A1 (en) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
| AU2012284088B2 (en) | 2011-07-19 | 2015-10-08 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
| WO2013066736A1 (en) * | 2011-11-03 | 2013-05-10 | Merck Sharp & Dohme Corp. | QUINOLINE CARBOXAMIDE AND QUINOLINE CARBONITRILE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE |
| JP5783264B2 (ja) | 2011-11-25 | 2015-09-24 | 日本電気株式会社 | セル識別子割当方法、基地局、保守サーバ、移動通信システム |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US20130281397A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| EP2666775A1 (en) | 2012-05-21 | 2013-11-27 | Domain Therapeutics | Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors |
| BR112014031896A2 (pt) * | 2012-06-20 | 2017-06-27 | Univ Vanderbilt | composto, composição farmacêutica, e, método para o tratamento de um distúrbio |
| WO2013192347A1 (en) | 2012-06-20 | 2013-12-27 | Vanderbilt University | Substituted bicyclic cycloalkyl pyrazole lactam analogs as allosteric modulators of mglur5 receptors |
| WO2013192350A1 (en) * | 2012-06-20 | 2013-12-27 | Vanderbilt University | Substituted bicyclic aralkyl pyrazole lactam analogs as allosteric modulators of mglur5 receptors |
| KR20150070187A (ko) * | 2012-10-23 | 2015-06-24 | 에프. 호프만-라 로슈 아게 | 자폐 장애의 치료를 위한 ｍｇｌｕ２／３ 길항제 |
| CN103772686B (zh) | 2012-10-26 | 2015-01-07 | 苏州雷纳药物研发有限公司 | 一种两亲性嵌段共聚物及其制备方法、以及该共聚物与抗肿瘤药物形成的胶束载药系统 |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| EP3174884B1 (en) | 2014-08-01 | 2018-09-26 | Janssen Pharmaceutica NV | 6,7-dihydropyrazolo[1,5- ]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglu2 receptors |
| EP3174882B1 (en) | 2014-08-01 | 2018-11-07 | Janssen Pharmaceutica NV | 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglu2 receptors |
| JO3601B1 (ar) | 2014-08-01 | 2020-07-05 | Janssen Pharmaceutica Nv | مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2 |
| JOP20150177B1 (ar) | 2014-08-01 | 2021-08-17 | Janssen Pharmaceutica Nv | مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2 |
| JOP20150179B1 (ar) * | 2014-08-01 | 2021-08-17 | Janssen Pharmaceutica Nv | مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2 |
| AU2015357167B2 (en) | 2014-12-03 | 2020-06-25 | Janssen Pharmaceutica Nv | 6,7-dihydropyrazolo(1,5-alpha)pyrazin-4(5H)-one compounds and their use as negative allosteric modulators of mGluR2 receptors |
| ES2727158T3 (es) | 2014-12-03 | 2019-10-14 | Janssen Pharmaceutica Nv | Ligandos para PET de mGluR2 radiomarcados |
| US11045562B2 (en) | 2015-12-18 | 2021-06-29 | Janssen Pharmaceutica Nv | Radiolabelled mGluR2/3 PET ligands |
| WO2017103182A1 (en) | 2015-12-18 | 2017-06-22 | Janssen Pharmaceutica Nv | Radiolabelled mglur2/3 pet ligands |
-
2015
- 2015-07-27 JO JOP/2015/0179A patent/JOP20150179B1/ar active
- 2015-07-30 MX MX2017001452A patent/MX376289B/es active IP Right Grant
- 2015-07-30 EA EA201692540A patent/EA031087B1/ru unknown
- 2015-07-30 LT LTEP15750666.8T patent/LT3177623T/lt unknown
- 2015-07-30 JP JP2017504775A patent/JP6662846B2/ja not_active Expired - Fee Related
- 2015-07-30 BR BR112017001726A patent/BR112017001726A2/pt not_active Application Discontinuation
- 2015-07-30 SI SI201530513T patent/SI3177623T1/sl unknown
- 2015-07-30 NZ NZ728122A patent/NZ728122A/en not_active IP Right Cessation
- 2015-07-30 PH PH1/2017/500161A patent/PH12017500161B1/en unknown
- 2015-07-30 ME MEP-2019-24A patent/ME03320B/me unknown
- 2015-07-30 ES ES15750666T patent/ES2708215T3/es active Active
- 2015-07-30 HR HRP20181997TT patent/HRP20181997T1/hr unknown
- 2015-07-30 EP EP15750666.8A patent/EP3177623B1/en active Active
- 2015-07-30 RS RS20190115A patent/RS58279B1/sr unknown
- 2015-07-30 US US15/500,600 patent/US10005786B2/en active Active
- 2015-07-30 PT PT15750666T patent/PT3177623T/pt unknown
- 2015-07-30 CN CN201580041316.8A patent/CN106573936B/zh active Active
- 2015-07-30 SG SG11201700638YA patent/SG11201700638YA/en unknown
- 2015-07-30 CA CA2954093A patent/CA2954093C/en active Active
- 2015-07-30 WO PCT/EP2015/067530 patent/WO2016016380A1/en not_active Ceased
- 2015-07-30 HU HUE15750666A patent/HUE042871T2/hu unknown
- 2015-07-30 SM SM20190038T patent/SMT201900038T1/it unknown
- 2015-07-30 KR KR1020177005257A patent/KR102531689B1/ko active Active
- 2015-07-30 PL PL15750666T patent/PL3177623T3/pl unknown
- 2015-07-30 AU AU2015295298A patent/AU2015295298B2/en not_active Ceased
- 2015-07-30 TW TW104124696A patent/TWI696624B/zh not_active IP Right Cessation
- 2015-07-30 TR TR2019/01074T patent/TR201901074T4/tr unknown
- 2015-07-30 MA MA39582A patent/MA39582B1/fr unknown
- 2015-07-30 DK DK15750666.8T patent/DK3177623T3/en active
- 2015-07-31 AR ARP150102461A patent/AR101392A1/es unknown
-
2017
- 2017-01-25 CL CL2017000192A patent/CL2017000192A1/es unknown
- 2017-01-26 IL IL250298A patent/IL250298A0/en active IP Right Grant
- 2017-01-31 ZA ZA2017/00759A patent/ZA201700759B/en unknown
-
2018
- 2018-05-10 US US15/976,037 patent/US10512646B2/en active Active
-
2019
- 2019-01-24 CY CY20191100101T patent/CY1121649T1/el unknown
- 2019-11-07 US US16/677,034 patent/US20200121677A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017000192A1 (es) | Compuestos de 6,7-dihidropirazolo[1,5-a]pirazin-4(5h)-ona y su uso como moduladores alostéricos negativos de receptores mglu2r2 | |
| CL2017000249A1 (es) | Compuestos de 6,7-dihidropirazolo [1,5-a] pirazin-4(5h)-ona y su uso como moduladores alostéricos negativos de receptores mglu2r2 | |
| ECSP19024046A (es) | Compuestos y composiciones como inhibidores de los receptores endosomales tipo peaje | |
| JO3368B1 (ar) | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 | |
| CL2017000271A1 (es) | Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias | |
| CL2017001923A1 (es) | Derivados de 9h-pirrolo-dipiridina | |
| CR20170484A (es) | Azabenzimidazoles y su uso como moduladores del receptor ampa | |
| BR112017001998A2 (pt) | compostos 6,7-di-hidropirazolo[1,5-a]pirazin-4(5h)-ona e seu uso como moduladores alostéricos negativos de receptores mglur2 | |
| CL2017000223A1 (es) | [1,2,4]triazolo[4,3-b]piridazinas para su uso en el tratamiento de enfermedades proliferativas | |
| MX365438B (es) | Compuestos de tipo 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostericos positivos de receptores mglur2. |